Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ESR2
REST API REST API
Homo sapiens
ESR2 is differentially expressed in 252 experiments: 131 organism parts: lung, skin, ... (129 more);, 201 disease states: normal, acute promyelocytic leukemia, ... (199 more);, 71 cell types 268 cell lines 21 compound treatments and 80 other conditions.
Synonyms NR3A2, Erb
Orthologs Esr2 (Rattus norvegicus)   ESR2_BOVIN (Bos taurus)   esr2b (Danio rerio)   ERR (Drosophila melanogaster)   F1NMB7_CHICK (Gallus gallus)   esr2a (Danio rerio)   Esr2 (Mus musculus)   esr2 (Xenopus laevis)   Q95JC0_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term negative regulation of cell growth, DNA binding, receptor antagonist activity, protein binding, regulation of transcription, DNA-dependent, regulation of cell proliferation, negative regulation of cell proliferation, ligand-dependent nuclear receptor activity, transcription, DNA-dependent, negative regulation of signal transduction, metal ion binding, cell-cell signaling, positive regulation of apoptosis, sequence-specific DNA binding, transcription coactivator activity, nucleus, steroid binding, receptor activity, nucleoplasm, negative regulation of epithelial cell proliferation, brain development, enzyme binding, steroid hormone receptor activity, signal transduction, mitochondrion, zinc ion binding, neuron migration, negative regulation of androgen receptor signaling pathway, steroid hormone mediated signaling pathway, estrogen receptor signaling pathway, epithelial cell maturation involved in prostate gland development, uterus development, intracellular receptor mediated signaling pathway, gene expression, ovarian follicle development, estrogen receptor activity, regulation of transcription from RNA polymerase II promoter by nuclear hormone receptor, prostate gland epithelium morphogenesis, vagina development, sequence-specific DNA binding transcription factor activity
InterPro Term Nucl_hrmn_rcpt_lig-bd_core, Str_hrmn_rcpt, Znf_hrmn_rcpt, Estrogen_rcpt_beta_N
UniProt Accession Q92731, Q7LCB3, F5GWJ8, F1D8N3
Search EB-eye ENSG00000140009
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, E-GEOD-2450, ... (25 experiments)

Factor Value U/D Experiments
MDA-MB-231
3
E-TABM-420, E-GEOD-5823, E-MTAB-62
HL-60
2
E-GEOD-5258, E-MTAB-37
GM15510
2
E-GEOD-19466, E-GEOD-22639
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
MCF-7
1
2
E-GEOD-5823, E-GEOD-3529, E-GEOD-20081
THP1
1
E-MTAB-37
262 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, ... (37 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3920, E-GEOD-26672
stromal cell
2
E-MEXP-2034, E-GEOD-10797
multipotent adult progenitor cell
1
E-MEXP-466
plasmablast
1
E-MEXP-2360
iPS cells from episomal vectors (Defined Factor sub-clone)
1
E-GEOD-20033
epithelioid malignant mesothelioma (MM)
1
E-GEOD-21750
65 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-MEXP-1121, E-MTAB-62, E-GEOD-5370, ... (54 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
prostate carcinoma
3
E-MTAB-62, E-MEXP-2034, E-GEOD-96
colon carcinoma
2
E-MTAB-62, E-MTAB-37
melanoma
2
E-MTAB-37, E-MTAB-62
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
chronic myelogenous leukemia
1
2
E-MTAB-37, E-MTAB-62, E-GEOD-5550
195 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-5824, E-GEOD-5099, E-MEXP-941, ... (15 experiments)

Factor Value U/D Experiments
none
1
3
E-GEOD-412, E-GEOD-5824, E-GEOD-7307, E-GEOD-2803
potassium dichromate
1
E-GEOD-6907
unknown
1
E-GEOD-7307
sapphyrin PCI-2054
1
E-GEOD-6400
vanadium pentoxide
1
E-GEOD-5339
interferon-gamma + lipopolysaccharide
1
E-GEOD-5099
15 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
85
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-2171, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-19246, E-GEOD-21374, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-GEOD-4006

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-MEXP-421, E-TABM-868, E-TABM-601, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-TABM-127, E-GEOD-20540, E-MEXP-1446, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-MEXP-2069, E-GEOD-1926, ... (37 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-980, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

No of metastases
studied in E-GEOD-22541

No of pulmonary metastases
studied in E-GEOD-22541

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-1295

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Processing time: 0.586 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM